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In young women, diﬀerentiated thyroid cancer is the second most commonmalignancy diagnosed around the time of pregnancy.
Management of thyroid cancer during pregnancy poses distinct challenges due to concerns regarding maternal and fetal well-
being. In most cases surgery can be safely delayed until after delivery and with adequate management and outcome of pregnancy
in womenwith thyroid cancer is excellent. Ideally thesepatients shouldbe managedby a multidisciplinaryteam,and management
plan should be determined by a consensus between the patient and the healthcare team.
1.Introduction
With the rising incidence of diﬀerentiated thyroid cancer
(DTC), particularly in younger women, DTC is the sec-
ond most common cancer diagnosed around the time of
pregnancy with a prevalence of 14 per 100,000 [1]. Normal
physiological changes occurring during pregnancy and con-
cerns regarding fetal well-being pose distinct challenges to
all aspects of DTC management. This paper reviews various
facets of DTC management during pregnancy based on the
published evidence and extensive clinical experience of the
authors.
2.IsPregnancya RiskFactorfor
Thyroid Cancer?
Since DTC has a threefold higher incidence in women
of reproductive age [2], an association between estrogen,
human chorionic gonadotropin (HCG), and DTC has
long been speculated. Several studies have suggested an
association between the risk of DTC and high parity
[3, 4], and there is also evidence that use of fertility
agent, clomiphene, in parous women is associated with a
higher risk of DTC [5]. The data regarding an association
between estrogen and DTC, however, are inconsistent, with
some studies reporting a pro-proliferative eﬀect of estrogen
on thyroid cancer cell lines [6], while others showing a
stimulatory eﬀect of estrogen on normal and adenomatous
thyroid only, but not on thyroid cancer [7]. The clinical
data are also conﬂicting; one study reported a higher risk
of DTC in women exposed to estrogen-containing oral
contraceptive and postmenopausal hormone replacement
therapy [8], while another study reported no association
between the use of exogenous estrogens and DTC [9].
Similar discordance exists in data regarding the outcome
of DTC diagnosed during pregnancy; for instance, one
study suggests that DTC diagnosed during pregnancy is
associated with poorer prognosis and is more likely to have
positive ERα expression as compared to tumours diagnosed
innongravidicperiod[10],whileanotherretrospective study
comparing the outcome of DTC diagnosed in pregnant
women with age-matched controls showed no signiﬁcant
diﬀerence in cancer recurrence or cancer-related death [11].
The data regarding the eﬀect of HCG on DTC are also
nonconﬁrmatory. Although rising HCG during pregnancy
has a stimulatory eﬀect on thyroid hormone production,
t h e r ei sn oe v i d e n c et od a t el i n k i n gH C Gw i t hD T C .I n
a large cohort of women treated with fertility drugs, the
use of HCG was not associated with a higher risk of DTC
[5]. In summary, therefore, epidemiologic data suggest an2 Journal of Thyroid Research
association between high parity and risk of DTC; but there
is lingering unclarity regarding the outcome of DTC that is
diagnosed during pregnancy.
3.ManagementofThyroid
CancerduringPregnancy
The management of DTC during pregnancy generally falls
into two clinical scenarios. One includes those women who
are diagnosed de novo with DTC during pregnancy, while
the other includes women with previous history of DTC
who haveeitherbecomepregnant orareplanning pregnancy.
Bothgroupspresentdistincttherapeuticchallengesrequiring
speciﬁc clinical approach based on disease stage, patient
preference, and stage of pregnancy.
3.1. Thyroid Surgery during Pregnancy. For most women
with newly diagnosed DTC or those with resectable macro-
scopic recurrence, a decision about whether or not to
perform surgery during pregnancy has to be made. This
questionisperhapsthebiggestsourceofvexationforpatients
and physicians alike. So far there has been no prospective
study comparing the outcomeof DTCin womenundergoing
surgery during pregnancy versus those where surgery was
delayed until after delivery. A retrospective, cross-sectional
study comparing 201 pregnant women undergoing thyroid
and parathyroid surgery with age-matched nonpregnant
controls reported that pregnant women had signiﬁcantly
longerhospital stay, higher hospital costs, and higher rates of
generalandendocrinecomplications[12].Anotherlargesur-
vey of almost thirteen thousand pregnant women reported a
signiﬁcantly higher risk of spontaneous abortion in women
who underwent surgery during gestation compared with
those who did not have surgery [13]. However, the risk of
surgery during pregnancy must be balanced against patients’
anxiety and perceived concern of tumour growth in case
surgery is delayed for several months. This question was
addressed through a retrospective study [11]t h a tc o m p a r e d
outcomes of DTC in 61 pregnant women with 528 age-
matched nonpregnant controls. Of pregnant women with
DTC, one underwent surgery in the ﬁrst trimester, twelve
in the second, and one in the third trimester, while most
of the patients underwent surgery after delivery. After a
median followup of 22.4 years, no signiﬁcant diﬀerences in
recurrence were observed between women who underwent
surgery during or after pregnancy.
Currently there is no consensus about the optimum tim-
ing ofsurgery for DTCin pregnancy [14],and individualized
decisions are generally based on patients’ wishes and other
risk factors, though most would agree that, in the absence
of aggressive disease, it is reasonable to delay surgery until
after delivery [15]. On the other hand, if surgery is to be
considered,forexample,incaseoflargetumour,compressive
symptoms, aggressive pathological or clinical features, rapid
enlargement of tumor, or patients’ concern, it should be
performed in the second trimester before 24-week gestation
[14] primarily due to an increased risk of spontaneous
abortion when surgery is performed in the ﬁrst trimester
[13].
In our interdisciplinary clinic setting (attended by an
endocrinologist, surgeon, and a radiation oncologist), we
stratify individual patient-risk based on several factors such
as cytological features (in case of newly identiﬁed DTC),
pathological aggressiveness and previous tumor behavior
(in case of recurrence), rapidity of growth, compressive
symptoms, and ultrasound features while also taking into
account patient’s wishes and concerns and the obstetrician’s
opinion before reaching a consensus. In the absence of
any high-risk features, we would normally prefer to delay
surgery until after delivery but we closely monitor patients
throughout pregnancy by performing neck ultrasound scans
during each trimester.
3.2. Radioiodine Therapy and Pregnancy. Radioiodine (131I)
administration during pregnancy is contraindicated due to
the sequelae of exposing the embryo or fetus to high doses
of radiation which include fetal hypothyroidism, attention
deﬁcit disorders, memory impairment, mental retardation,
malformations, growth changes, induction of malignancies
including leukemia, and lethal changes [16]. Women sched-
uled to have radioiodine therapy should exclude pregnancy
with appropriate testing beforehand [14].
131I should not be given to nursing women [14] due to
the signiﬁcant accumulation of 131I in the lactating breast
a n di t se x c r e t i o ni nb r e a s tm i l k[ 16]. As most thyroid cancers
are slowgrowing,delaying 131Itherapytoallowbreastfeeding
for a short duration may be considered through discussions
between the patient and the treating physician. Postpartum
131I therapy should be deferred for at least 6–8 weeks after
lactating women have stopped breastfeeding [14]. There is
a paucity of reliable data on the kinetics of 131Ie x c r e t i o ni n
breast milk. Therefore, after 131I therapy, it is recommended
that breastfeeding should only be resumed with the birth
of another child [17, 18]. In order to avoid stagnation
of 131I in the lactating breast and minimize the risk of
breast radiation exposure, suppression of lactation through
dopaminergic agents has been utilized but this should only
beused verycautiously[14] after discussion with thepatient.
Although one large study suggested a possible increase in
miscarriage rate if conception occurred within 6 months
of 131It h e r a p y[ 19], subsequent studies failed to conﬁrm
adverse outcomes for pregnancies or oﬀspring related to
previous 131It h e r a p y[ 20]. A conservative recommendation
is that women receiving radioiodine therapy should avoid
pregnancy for 6–12 months [14] to prevent any increase in
risk of infertility, miscarriage, or fetal malformation [21].
3.3. Thyroid Hormone Replacement during Pregnancy. Most
women undergoing subtotal or total thyroidectomy for DTC
require thyroid hormone replacement. Adequate thyroid
hormone levels are crucial for maternal and fetal well-
being, and several studies have reported that even mild
hypothyroidism during pregnancy is associated with both
adverse maternal and fetal outcomes. For instance, one
study showed that children of women with undiagnosedJournal of Thyroid Research 3
hypothyroidism during pregnancy had lower IQ score than
their age-matched controls [22]. In another study of women
without overt thyroid dysfunction, the risk of miscarriage,
fetalorneonatal deathincreased by 60%witheverydoubling
in TSH concentration [23]. However, the data regarding
low TSH in pregnancy is relatively reassuring, and, in a
large survey of 25,765 women of which 433 had subclinical
hyperthyroidism, low TSH was not associated with adverse
outcomes [24].
The two major challenges in assessing and replacing
thyroid hormones during pregnancy are emulating various
physiological changes occurring in the thyroid gland dur-
ing pregnancy and limitations of the commonly utilized
laboratory tests for testing thyroid function. The thyroid
gland undergoes remarkable changes during pregnancy. A
rising HCG in early pregnancy, due to its similarity to
thyroid-stimulating hormone (TSH), promotes the release
of thyroid hormones which consequently leads to a transient
drop in serum TSH values. At the same time, an increasing
estrogenlevelcausestwo-tothreefoldriseinthyroid-binding
globulin which alters the measured levels of total thyroxine
(T4) and triiodothyronine (T3) and to some extent free
thyroidhormonesaswell [25],thuslimitingtheusefulnessof
thyroid hormone measurement. This is further complicated
by the fact that there can be a wide interassay variability in
measured thyroid hormones during pregnancy [26]. Several
other factors such as gestational age and singleton versus
multiple-birth pregnancy can also alter thyroid hormone
levels,inparticularserumTSHvalues[27,28].Alargesurvey
of over thirteen thousand pregnant women reported a much
tighter reference range for TSH especially in early pregnancy
(2.5th and 95th percentiles of 0.1mIU/L and 2.5mIU/L,
resp.), as compared with general population [27]. Based
on these physiological variations, it is ideal to use gesta-
tional age-speciﬁc reference ranges expressed as multiples
of the median, instead of reference values based on general
population; however, most commercial assays do not quote
pregnancy-speciﬁc reference values. Recently more elaborate
techniques such as liquid chromatography-tandem mass
spectrometry and equilibrium dialysis have been utilized to
assess serum T4 in pregnancy [29, 30], but, apart from being
much more expensive and time consuming, the correlation
between free T4 measured through these techniques and
serum TSH in pregnancy remains poor [29]. Furthermore,
the requirement for thyroid hormone replacement increases
by as much as 20–40% during pregnancy starting as early as
the ﬁrst few weeks of gestation [31, 32]. Due to its long half-
life, T4 administration can take as much as 4–6 weeks before
reaching a steady state in plasma.
Withthese multiplefactors, pursuing anarrow therapeu-
tic TSH target during pregnancy can be quite challenging.
One study looked at the eﬀect of empirically increasing
the dose of thyroxin replacement immediately upon con-
ﬁrmation of pregnancy and concluded that giving an extra
two tablets of thyroxin each week signiﬁcantly reduces the
risk of maternal hypothyroidism during the ﬁrst trimester
and mimics the normal physiology [33]. One caveat with
this study was that patients who were athyreotic, those
requiring a prepregnancy thyroxin dose of at least 100μg/d,
and those with prepregnancy serum TSH concentrations
below 1.5mIU/liter had the highest risk for developing TSH
suppression and required subsequent dose modiﬁcations
after the initial intervention.
In our centre, whenever possible, we typically begin the
management of these patients with proper prepregnancy
counseling by informing our patients about the rationale
for more frequent TSH testing and the need for dose
adjustment. In addition, we make patients aware of the
possibility of reduced thyroxin absorption with commonly
used prepregnancy supplements such as iron and calcium
andadvisetotakethemseparatelyfromtheirthyroxin.Those
who are already taking suppressive TSH therapy and are
planning to get pregnant are typically advised to reduce the
dose of thyroxin aiming for a TSH in the range of 0.5–
2.5mIU/L. Upon conﬁrmation of pregnancy, the dose is
increased by an additional two tablets each week if TSH is
≥1.5mIU/L and by one tablet if TSH is <1.5mIU/L. Serum
TSHlevelsarecheckedevery4–6weeksandthedoseadjusted
to achieve and maintain TSH in the range of 0.5–2.5mIU/L
during pregnancy.
3.4. Followup of Thyroid Cancer during Pregnancy. Most
pregnant women with low-risk DTC require little more than
routine TSH monitoring and periodic clinical examination
during pregnancy. Radioactive iodine scan or stimulated
thyroglobulin (Tg) estimation through either thyroid hor-
mone withdrawal or recombinant TSH (Thyrogen) is not
justiﬁable in pregnancy. Several studies have reported that
although serum Tg levels can vary signiﬁcantly during each
trimester, the overall values remain well within the normal
nonpregnant range [34–36].
In our centre, we devise our followup strategy for such
patients based on their risk factors. Pregnant women with
low-risk DTC who were regarded free of disease prior to
pregnancy, aside from their thyroxin dose adjustment, are
followed on a three monthly (once in each trimester) basis
with an unstimulated Tg, and a thorough neck examination
is conducted at each visit. Those women who have high-
risk DTC or had documented recurrence of DTC prior to
pregnancy are followed more rigorously on a three monthly
basis with unstimulated Tg and neck ultrasonography.
Normal reference ranges for serum Tg are irrelevant for
followup of such patients, and decision regarding cancer
progress is based on their prepregnancy Tg levels as well as
ultrasonography ﬁndings.
4.The RoleofMultidisciplinaryTeamin
Managementof ThyroidCancer
Outside specialist centers, DTC patients have traditionally
been managed by a variety of specialties which leads to
an inconsistent and fragmented care, borne out by sev-
eral studies from various centers [37–39]. Patient surveys
have also conﬁrmed poor and inconsistent coordination
of thyroid cancer care among diﬀerent caregivers [40].
Over the past decade, several centers of excellence have
developed models of multidisciplinary teams comprising4 Journal of Thyroid Research
surgeons, radiologists, pathologists, endocrinologists, and
allied specialists to deliver coordinated care within hospitals
which ensures that each individual patient gets appropriate
treatment decision made by a team of experts [41]. In our
centre, all DTC patients (including pregnant females) are
assessed and followed by a team of specialists including
a surgeon, an endocrinologist, a radiation oncologist, a
dietitian, specialist nurses and, in case of pregnant women,
theteamworks closelywithanobstetricianand gynecologist.
In our opinion, pregnant women with DTC should ideally
be referred to a specialist centre but, in the absence of such
facility,managementdecisionsshouldbemadethroughclose
cooperation of all caregivers and the patient.
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